Immunotherapy After Targeted Drug Shows Promise in Advanced Liver Cancer – Curetoday.com
|
Immunotherapy After Targeted Drug Shows Promise in Advanced Liver Cancer
Curetoday.com Treatment with the PD-1 inhibitor Keytruda (pembrolizuumab) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced hepatocellular carcinoma (HCC) who received previous treatment with Nexavar … |
